首页|骨质疏松症的治疗新药研发展望

骨质疏松症的治疗新药研发展望

扫码查看
随着人口老龄化加剧,骨质疏松症的患病率快速攀升,其已成为日益严重的公共健康问题.目前我国强有效的抗骨质疏松治疗药物种类十分不足,难以遏制疾病日益增长的流行趋势.骨质疏松症发生的关键病理机制是骨稳态失衡,需要不断深入研究骨骼细胞生物学、骨稳态的重要调控通路,以及骨骼-肌肉-血管-免疫-神经-肠道菌群等构成的骨稳态调控网络,以寻找新药研发的关键靶点,研发更多有效药物,提高患者的骨密度、改善骨强度,降低骨折风险,为骨骼健康保驾护航.
Prospects for the development of new drugs for the treatment of osteoporosis
With the population aging,the prevalence of osteoporosis is rapidly increasing,which has become serious public health problem.At present,there is a severe shortage of effective anti-osteoporotic drugs in China,making it difficult to control the growing trend of osteoporosis.The key pathological mechanism of osteoporosis is bone homeostasis imbalance.It is necessary to continuously study the bone cell biology,important pathway regulating bone homeostasis,and its regulatory network constituted by bone-muscle-vessel-immune system-nerve-gut microbiota,in order to identify key targets for new drug,and develop more novel effective drugs to increase bone mineral density,improve bone strength,reduce fracture risk and protect bone health.

OsteoporosisBone homeostasis imbalanceNovel targeted therapeutic drugs

李梅

展开 >

中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室,北京 100730

骨质疏松 骨稳态失衡 新型靶向治疗药物

2025

中华医学杂志
中华医学会

中华医学杂志

北大核心
影响因子:1.477
ISSN:0376-2491
年,卷(期):2025.105(1)